Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

9.640 +0.550 (+6.05%)
Streaming Delayed Price Updated: 3:24 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation 
From Emergent BioSolutions
Via GlobeNewswire
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Addition to Russell 3000® Index
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
From Emergent BioSolutions
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Emergent BioSolutions Reports First Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.